Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped COVID-19 Pandemic interfered with Pt recruitment

Conditions

Type2 Diabetes
Major Depressive Disorder

Interventions

DRUG: Vortioxetine

Sponsor

Todd Doyle

Collaborators

[object Object]